Thinking Beyond Glycemia: The Importance of Managing Heart Failure Risks in Type 2 Diabetes
Join us as we examine the risk of hospitalization for heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF risk reduction in patients with T2D and CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA (dapagliflozin) being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.
Dr. Michael Cobble
Director and Clinician
Canyons Medical Center
INDICATIONS AND LIMITATIONS OF USE for FARXIGA® (dapagliflozin) 5 mg and 10 mg tablets
FARXIGA is indicated:
FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
IMPORTANT SAFETY INFORMATION for FARXIGA
Warnings and Precautions
In a pool of 12 placebo-controlled studies, the most common adverse reactions (≥5%) associated with FARXIGA 5 mg, 10 mg, and placebo respectively were female genital mycotic infections (8.4% vs 6.9% vs 1.5%), nasopharyngitis (6.6% vs 6.3% vs 6.2%), and urinary tract infections (5.7% vs 4.3% vs 3.7%).
Use in Specific Populations
Please see full US Prescribing Information for FARXIGA.